Translational medicine--a paradigm shift in modern drug discovery and development: the role of biomarkers.

The success rate of novel medical entities that are submitted for registration by the regulatory agencies and followed successful marketing has been stagnating for the past decade. Failure in efficacy and safety continue to be the prime hurdles and causes of failure. Translational medicine is a new function within the pharmaceutical industry R&D organization aimed to improve the predictability and success of drug discovery and development. Biomarkers are the essence of the translational medicine strategy focus on disease biomarker, patient selection, pharmacodynamic responses (efficacy and safety) target validation, compound-target interaction). Successful deployment of biomarkers research, validation and implementation is adopted and embraced as key strategy to improved the drug discovery and development towards new medical entities.

[1]  R. Kurzrock.  Studies in target-based treatment , 2007, Molecular Cancer Therapeutics.

[2]  Mark R. Trusheim,et al.  Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers , 2007, Nature Reviews Drug Discovery.

[3]  Glyn Lewis,et al.  A longitudinal study of premorbid IQ Score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses. , 2004, Archives of general psychiatry.

[4]  S. Iritani.  Neuropathology of schizophrenia: A mini review , 2007, Neuropathology : official journal of the Japanese Society of Neuropathology.

[5]  K. Chien.  Herceptin and the heart--a molecular modifier of cardiac failure. , 2006, The New England journal of medicine.

[6]  Michael F. Green,et al.  Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: A double-blind, randomized controlled trial , 2007, Schizophrenia Research.

[7]  M. Krams,et al.  Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.

[8]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[9]  G. Feuerstein,et al.  Renin inhibitors: An antihypertensive strategy on the verge of reality , 2005 .

[10]  Michael F. Green,et al.  Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. , 2006, The Journal of clinical psychiatry.

[11]  Zhuoxin Sun,et al.  The Influence of Chronic Exposure to Antipsychotic Medications on Brain Size before and after Tissue Fixation: A Comparison of Haloperidol and Olanzapine in Macaque Monkeys , 2005, Neuropsychopharmacology.

[12]  D. Berry.  Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.

[13]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[14]  Andrew P Grieve,et al.  Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke , 2003, Stroke.